Adalimumab an ADEPT treatment for psoriatic arthritis

The anti-tumour necrosis factor (TNF)-α monoclonal antibody adalimumab is effective in treating the signs and symptoms of psoriatic arthritis, according to data presented at the 63rd Annual Meeting of the American Academy of Dermatology (AAD) [New Orleans, Louisiana, US; February 2004]. Results from the ADEPT study showed that adalimumab produced significant improvements in skin and joint symptoms, compared with placebo. In a second study, adalimumab produced comparable results in patients who had psoriasis with or without psoriatic arthritis.